Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial

BACKGROUND: Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cysti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cipolla, David, Zhang, Jimin, Korkmaz, Brice, Chalmers, James D., Basso, Jessica, Lasala, Daniel, Fernandez, Carlos, Teper, Ariel, Mange, Kevin C., Perkins, Walter R., Sullivan, Eugene J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189992/
https://www.ncbi.nlm.nih.gov/pubmed/37198686
http://dx.doi.org/10.1186/s12931-023-02444-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189992/
https://www.ncbi.nlm.nih.gov/pubmed/37198686
http://dx.doi.org/10.1186/s12931-023-02444-z

Ejemplares similares